8 septiembre 2015
Many cancers include increased copies of the gene MET. But in which cases is MET driving the cancer and in which do these increased copies happen to «ride along» with other molecular abnormalities that are the true cause of the disease? A study defines criteria for MET-amplified cancer likely sensitive to treatment with crizotinib.
http://www.sciencedaily.com/releases/2015/09/150908144150.htm
